Evolus Inc (NASDAQ:EOLS)’s share price fell 5.6% on Monday . The company traded as low as $21.11 and last traded at $22.19. 734,666 shares changed hands during trading, a decline of 27% from the average session volume of 999,827 shares. The stock had previously closed at $23.51.
A number of research firms have weighed in on EOLS. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Tuesday, March 19th. SunTrust Banks began coverage on Evolus in a research note on Wednesday, March 20th. They set a “buy” rating and a $30.00 price objective on the stock. HC Wainwright began coverage on Evolus in a research note on Thursday, February 14th. They set a “buy” rating and a $37.00 price objective on the stock. Zacks Investment Research lowered Evolus from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Finally, Mizuho boosted their price objective on Evolus from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $30.71.
The company has a debt-to-equity ratio of 0.96, a current ratio of 14.80 and a quick ratio of 14.52. The firm has a market cap of $606.52 million, a PE ratio of -13.87 and a beta of 5.01.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in shares of Evolus by 104.9% during the third quarter. BlackRock Inc. now owns 615,719 shares of the company’s stock worth $11,465,000 after buying an additional 315,210 shares during the period. Inverness Counsel LLC NY acquired a new stake in Evolus in the fourth quarter worth $190,000. Citigroup Inc. raised its holdings in Evolus by 4,361.6% in the fourth quarter. Citigroup Inc. now owns 24,851 shares of the company’s stock worth $296,000 after purchasing an additional 24,294 shares during the period. Bank of New York Mellon Corp raised its holdings in Evolus by 32.6% in the third quarter. Bank of New York Mellon Corp now owns 20,367 shares of the company’s stock worth $379,000 after purchasing an additional 5,005 shares during the period. Finally, Chartwell Investment Partners LLC acquired a new stake in Evolus in the fourth quarter worth $903,000. Hedge funds and other institutional investors own 19.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Evolus (EOLS) Stock Price Down 5.6%” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2019/05/15/evolus-eols-stock-price-down-5-6.html.
About Evolus (NASDAQ:EOLS)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.